

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Ortho Regenerative Technologies Inc. (the “Company” or the “Issuer”)**

Trading Symbol: **ORTH**

Number of Outstanding Listed Securities: **24,712,424**

Date: **July 5, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company continues to implement operational initiatives to meet its business objectives including the administration and execution of its pre-clinical development plan and prosecution for its four patent families.

2. Provide a general overview and discussion of the activities of management.

In the period, Management’s primary focus was to:

- (i) **Pursue the activities relating to our pre-clinical and clinical development of ORTHO-R, our lead program for rotator cuff repair.**

- (ii) **Execute any required research and development, regulatory, manufacturing, or operational activities required to support the above initiatives, either internally or through the company's partners and key suppliers.**
 - (iii) **Actively promote itself to strategic partners interested in our biopolymer technology and/or active programs.**
 - (iv) **Initiate planning activities for proof-of-concept studies relating to the use of our Ortho-M products for the treatment/repair of meniscus tear.**
 - (v) **Actively promote itself to potential institutional, and retail investors including life science analysts, in order to raise the capital required to fund its operations.**
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
- Nothing applicable during the period.**
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
- Nothing applicable during the period.**
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
- Nothing applicable during the period.**
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
- Nothing applicable during the period.**
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
- Nothing applicable during the period.**
8. Describe the acquisition of new customers or loss of customers.
- Nothing applicable during the period.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks

Nothing applicable during the period.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

Concurrent to the senior management changes announced on June 17, 2019 (see 17 below), the VP Development position has been abolished and the new CEO has taken over responsibilities previously assigned to this role.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Nothing applicable during the period.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Nothing applicable during the period.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

14. Provide details of any securities issued and options or warrants granted.

- **On June 20th, in connection with Mr. Laurin's appointment to the Issuer's Board (see section 16 below), the Company has granted 100,000 share options to Mr. Laurin.**
- **The Company has also granted 500,000 share options to Mr. LeDuc, in accordance with the terms of his engagement as President and CEO (see section 16).**
- **Finally, the Company has granted an aggregate of 150,000 share options to two consultants. All share options were granted pursuant to the Company's Share Option Plan and will vest pursuant to the respective option agreements between the Company and each optionee.**

All options mentioned above may be exercised at an exercise price of CAD\$0.36 per Class A share, for a period of 5 years from the date of issuance. .

15. Provide details of any loans to or by Related Persons.

No new loans with related parties in the current period

16. Provide details of any changes in directors, officers or committee members.

On June 17th, the Company announced the nomination of Claude LeDuc as its new President and CEO in replacement of Dr. Brent Norton who is stepping down from his operational role to focus on other initiatives. Dr. Norton will remain on the Board of Directors of the Company.

On June 20th, the Company announced the appointment of Messrs. Pierre Laurin and Claude LeDuc to its Board of Directors. The nominations are effective as of June 19, 2019.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

None in the current period.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: July 5th, 2019

Ortho Regenerative Technologies Inc.
 /s/ Luc Mainville
Senior VP & Chief Financial Officer
 Official Capacity

Issuer Details		For Month End	Date of Report
Name of Issuer			YY/MM/D
Ortho Regenerative Technologies Inc.		June 2019	2019/07/05
Issuer Address			
16667, Boul. Hymus,			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Kirkland, Quebec, H9H 4R9		514.694.0443	514.694.0865
Contact Name		Contact Position	Contact Telephone No.
Luc Mainville		Sr. VP & CFO	(514) 693-8854
Contact Email Address		Web Site Address	
mainville@orthorti.com		www.orthorti.com	